RAPT RAPT Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 23 May 2022 RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

   SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).
   

   "We are excited to advance RPT193 into this Phase 2b trial in atopic dermatitis," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "Our Phase 1b trial results support the…

   View Full Article
2. 11 May 2022 RAPT Therapeutics Reports First Quarter 2022 Financial Results

   SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter ended March 31, 2022.
   

   "As we kick off 2022, we continue to make strong and steady progress in our programs in inflammatory diseases and oncology," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "Recently, at the American Academy of Dermatology annual meeting, we reported biomarker data from our Phase 1b clinical trial of RPT193…

   View Full Article
3. 04 May 2022 RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

   SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointments of Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations and Shari Geffon as Vice President of Program and Alliance Management.
   

   "We are pleased to attract such high caliber talent as we continue to grow our organization and make advances in our inflammatory disease and cancer programs. Gwen is a strategic business leader with a wealth of…

   View Full Article
4. 28 March 2022 RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

   SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced biomarker data from the company's randomized placebo-controlled Phase 1b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis (AD) were consistent with previously reported top-line data which showed clear improvement in key exploratory efficacy measures. The biomarker data, which were presented in a late-breaking oral session at the American Academy of Dermatology Annual Meeting…

   View Full Article
5. 10 March 2022 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

   SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2021.
   

   "2021 was a significant year for RAPT, with progress in both of our lead programs," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "We reported positive results for RPT193 from our Phase 1b clinical trial in atopic dermatitis and are excited about RPT193's potential as a safe, once-daily…

   View Full Article